|
ZNF550 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.5620000000105E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.9846000004774E-07 |
| Normal-vs-Stage2 |
6.09299999999591E-05 |
| Normal-vs-Stage3 |
2.20470000034112E-07 |
| Normal-vs-Stage4 |
9.92990000225902E-08 |
| Stage1-vs-Stage2 |
4.570600E-01 |
| Stage1-vs-Stage3 |
1.416770E-01 |
| Stage1-vs-Stage4 |
1.385840E-02 |
| Stage2-vs-Stage3 |
7.501000E-01 |
| Stage2-vs-Stage4 |
2.501200E-01 |
| Stage3-vs-Stage4 |
3.243800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.35380000002117E-06 |
| Normal-vs-AfricanAmerican |
6.281500E-03 |
| Normal-vs-Asian |
4.595100E-04 |
| Caucasian-vs-AfricanAmerican |
6.686600E-01 |
| Caucasian-vs-Asian |
6.857800E-01 |
| AfricanAmerican-vs-Asian |
9.160600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.90270000053484E-07 |
| Normal-vs-Female |
1.62759999999817E-06 |
| Male-vs-Female |
8.248600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.98456999999097E-05 |
| Normal-vs-Age(41-60Yrs) |
1.09080000032513E-07 |
| Normal-vs-Age(61-80Yrs) |
3.77080000002472E-07 |
| Normal-vs-Age(81-100Yrs) |
4.766200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.252800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.796200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.191600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.001800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.566000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.674000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.121020E-03 |
| Classical-VS-Follicular |
5.571700E-02 |
| Classical-VS-Other |
7.314800E-01 |
| Classical-VS-Normal |
6.34990000000224E-05 |
| Tall-VS-Follicular |
2.114800E-01 |
| Tall-VS-Other |
5.071600E-01 |
| Tall-VS-Normal |
4.30340000301399E-08 |
| Follicular-VS-Other |
7.897600E-01 |
| Follicular-VS-Normal |
7.67119999967036E-07 |
| Other-VS-Normal |
6.445700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.23259999996029E-07 |
| Normal-vs-N1 |
3.71750000000004E-05 |
| N0-vs-N1 |
4.619000E-01 |
|
|
